Detalhe da pesquisa
1.
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Lancet Oncol
; 24(8): 868-880, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37423227
2.
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
Lancet Oncol
; 21(11): 1478-1488, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33128873
3.
Dysphagia-optimised intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply.
Lancet Oncol
; 24(10): e398, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37797636
4.
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
Eur J Cancer
; 205: 114103, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38729054
5.
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Cancer Discov
; 11(1): 92-107, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32958578
6.
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Cancer Discov
; 10(10): 1528-1543, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32532747